Introduction {#s1}
============

Acquired prolongation of QT interval increases the risk of ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death (SCD). However, patients with prolonged QT intervals are heterogeneous in that only a subset develop these adverse events and risk stratification remains difficult. Of the different electrophysiological mechanisms, exacerbated repolarization gradient across the myocardial wall has been identified as an important factor of arrhythmogenesis in the context of QT prolongation, as it can lead to unidirectional block and reentrant activity (Opthof et al., [@B21]; Coronel et al., [@B3]; Choy et al., [@B2]). On the electrocardiogram, the dispersion of repolarization can be estimated using the T~peak~ -- T~end~ Interval, defined as the time difference between the peak and the end of the T-wave. However, this parameter varies with heart rate (Gupta et al., [@B9]) and normalization with QT interval (T~peak~ -- T~end~/QT ratio) gives a relatively constant range of values between 0.17 and 0.23 (Gupta et al., [@B9]). Despite their strong physiological basis, the predictive value of both parameters in drug-induced QT prolongation remains controversial.

A recent meta-analysis reported that higher T~peak~ -- T~end~ interval was predictive of adverse events that include ventricular tachyarrhythmias and sudden cardiac death in congenital long QT syndrome, but it did not investigate its value in cases of acquired QT interval prolongation (Tse et al., [@B30]). Nevertheless, several reports have investigated the differences in T~peak~ -- T~end~ interval and/or T~peak~ -- T~end~ / QT ratio between event-positive and event-negative subjects with acquired QT prolongation with some conflicting results. In this study, we performed a systematic review and meta-analysis to elucidate the relationship between these parameters and adverse events in this patient population.

Methods {#s2}
=======

Search strategy, inclusion, and exclusion criteria
--------------------------------------------------

This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISM) statement (Moher et al., [@B18]). PubMed, Embase and Cochrane Library were searched for studies that investigated the association between T~peak~ -- T~end~ or T~peak~ -- T~end~/QT with arrhythmic or mortality endpoints in long QT syndrome. The following search terms were used for all three databases: \["Tpeak--Tend" OR "Tp-Te" OR "Tpeak-end" OR "Tp-e" OR "T(peak)-T(end)" OR "T wave peak-to-end" OR "T peak-T end" OR "Tpe" "TPEc" OR "T-peak to T-end" OR "Tpeak-to-Tend" AND "long QT"\]. The search period was from the beginning of the database through to 14th February 2018 without language restrictions. The following inclusion criteria were used: (i) the study was conducted in humans, (ii) T~peak~ -- T~end~ intervals or T~peak~ -- T~end~/QT ratios between event-positive (ventricular tachycardia/fibrillation, or sudden cardiac death) and event-negative groups were compared.

The quality assessment of these studies included in our meta-analysis was performed using the Newcastle--Ottawa Quality Assessment Scale (NOS; Marshall et al., [@B17]). The details of the NOS quality assessment are shown in Supplementary Tables [1](#SM1){ref-type="supplementary-material"}, [2](#SM1){ref-type="supplementary-material"}. No studies were excluded because of the quality score.

Data extraction and statistical analysis
----------------------------------------

Data from the different studies were entered in pre-specified spreadsheets in Microsoft Excel (Version 2016). All search entries were retrieved as complete manuscripts and assessed to determine whether they met the inclusion criteria. The extracted data elements consisted of: (i) publication details: last name of first author, publication year; (ii) study design; (iii) endpoint(s); (iv) the quality score; and (v) the characteristics of the population including sample size, gender, age and number of subjects. Two reviewers (GT and MG) reviewed each included study independently. Disagreements were resolved by consulting with a third reviewer (TL).

Mean differences with 95% confidence interval (CI) for T~peak~ -- T~end~ interval and T~peak~ -- T~end~/QT ratio were extracted from each study and subsequently pooled. Heterogeneity between studies was determined using Cochran\'s *Q*-value, the weighted sum of squared differences between individual study effects and the pooled effect across studies, and *I*^2^ from the standard chi-square test, which describes the percentage of the variability in effect estimates resulting from heterogeneity. *I*^2^ \> 50% was considered to reflect significant statistical heterogeneity. A fixed effects model was used if *I*^2^ \< 50%, otherwise the random-effects model using the inverse variance heterogeneity method was used. To locate the origin of the heterogeneity, sensitivity analysis excluding one study at a time were performed. Funnel plots, Begg and Mazumdar rank correlation test and Egger\'s test were used to assess for possible publication bias.

Results {#s3}
=======

A flow diagram of the search strategy is shown in Supplementary Figure [1](#SM1){ref-type="supplementary-material"}. Our search retrieved 99 entries from PubMed, 116 entries from Embase and 17 from Cochrane Library. Of these, five studies were relevant for acquired LQTS and were included in our final meta-analysis (Yamaguchi et al., [@B37]; Topilski et al., [@B27]; Darbar et al., [@B7]; Couderc et al., [@B4]; Subbiah et al., [@B24]). A total of 308 patients were included (mean age: 66 ± 18 years old; 46% male). Table [1](#T1){ref-type="table"} shows the baseline characteristics of these studies and of the study populations.

###### 

Characteristics of the five studies included in this meta-analysis.

  **First author/Year**   **Study design**   **Population**                           **Drugs**                                                                                                                                                                                                                      **Lead for T~peak~--T~end~ measurement**   **Method of T~end~ measurement**   **Adverse events**   **Sample size (*n*)**   **Age**   **% Male**   **Endpoints**   **No. of patients with any positive events**   **References**
  ----------------------- ------------------ ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------ ---------------------------------- -------------------- ----------------------- --------- ------------ --------------- ---------------------------------------------- --------------------------
  Couderc 2010            Retrospective      Drug-induced LQTS                        Sotolol                                                                                                                                                                                                                        All 12 leads                               Tangent method                     TdP                  6                       50        67           TdP             3                                              Couderc et al., [@B4]
  Subbiah 2010            Prospective        AV block with TdP                        --                                                                                                                                                                                                                             All 12 leads                               Tangent method                     TdP                  40                      70        40           TdP             7                                              Subbiah et al., [@B24]
  Darbar 2008             Retrospective      Drug-induced LQTS                        Quinidine; sotalol, dofetilide, procainamide, disopyramide, amiodarone, trimethoprim-sulfamethoxazole, phenothiazines, Haloperidol, Fluconazole /itraconazole, cisapride, pentamidine, lithium, terfernadine, clarithromycin   All 12 leads                               Baseline method                    TdP                  123                     59        20           TdP             83                                             Darbar et al., [@B7]
  Topilski 2007           Retrospective      AV block with TdP                        --                                                                                                                                                                                                                             All 12 leads                               Baseline method                    TdP                  143                     76        19           TdP             30                                             Topilski et al., [@B27]
  Yamaguchi 2003          Prospective        Drug-induced LQTS (10 different drugs)   Bepridil, pirmenol, ranitidine, disopyramide, probucol, aprindine, diazepam, pilsicainide, clonazepam                                                                                                                          V5                                         Tangent method                     TdP                  27                      66        29           TdP             12                                             Yamaguchi et al., [@B37]

*LQTS, long QT syndrome; TdP, torsade de pointes*.

The T~peak~ -- T~end~ intervals for event-negative (Figure [1A](#F1){ref-type="fig"}, top panel) and event-positive groups (Figure [1A](#F1){ref-type="fig"}, middle panel) were 96 ± 14 and 165 ± 15, respectively, with a significant mean difference of 76 ± 26 ms (*P* = 0.003, *I*^2^ = 98%) (Figure [1A](#F1){ref-type="fig"}, bottom panel). Moreover, the T~peak~ -- T~end~/QT ratio for event-negative (Figure [1B](#F1){ref-type="fig"}, top panel) and event-positive (Figure [1B](#F1){ref-type="fig"}, middle panel) groups were 0.19 ± 0.01 and 0.29 ± 0.04, respectively, with a significant mean difference of 0.14 ± 0.03 (*P* \< 0.0001; *I*^2^ = 29%) (Figure [1B](#F1){ref-type="fig"}, bottom panel). The results from bias analyses are shown in the [Supplementary Material](#SM1){ref-type="supplementary-material"}.

![Forest plot demonstrating the **(A)** mean T~peak~ -- T~end~ intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and **(B)** mean T~peak~ -- T~end~/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation.](fphys-09-01226-g0001){#F1}

Subgroup analysis based on the cause of acquired LQTS was performed. A meta-analysis of three studies examining drug-induced LQTS found that T~peak~ -- T~end~ intervals for event-negative (Figure [2A](#F2){ref-type="fig"}, top panel) and event-positive groups (Figure [2A](#F2){ref-type="fig"}, middle panel) took values of 108 ± 19 and 149 ± 16, respectively. However, the mean difference of 44 ± 28 ms did not reach statistical significance (*P* = 0.12; I^2^ = 94%; Figure [2A](#F2){ref-type="fig"}, bottom panel). T~peak~ -- T~end~ / QT ratios took values of 0.20 ± 0.02 and 0.27 ± 0.05 for event-negative (Figure [2B](#F2){ref-type="fig"}, top panel) and event-positive (Figure [2B](#F2){ref-type="fig"}, middle panel) groups, respectively, with a significant mean difference between both groups (0.13 ± 0.03, *P* \< 0.0001; I^2^ = 22%; Figure [2B](#F2){ref-type="fig"}, bottom panel).

![Forest plot demonstrating the **(A)** mean T~peak~ -- T~end~ intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and **(B)** mean T~peak~ -- T~end~/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in drug-induced QT prolongation.](fphys-09-01226-g0002){#F2}

For AV block-induced LQTS, two studies were meta-analyzed. T~peak~ -- T~end~ intervals for event-negative (Figure [3A](#F3){ref-type="fig"}, top panel) and event-positive groups (Figure [3A](#F3){ref-type="fig"}, middle panel) were 79 ± 14 and 194 ± 49, respectively, leading to a significant mean difference of 124 ± 54 ms (*P* = 0.02; I^2^ = 99%; Figure [3A](#F3){ref-type="fig"}, bottom panel). By contrast, T~peak~ -- T~end~ / QT ratios took values of 0.18 ± 0.06 and 0.5 ± 0.06 for event-negative (Figure [3B](#F3){ref-type="fig"}, top panel) and event-positive (Figure [3B](#F3){ref-type="fig"}, middle panel) groups, respectively, but the mean difference between both groups was not significant (0.13 ± 0.11, *P* = 0.27; I^2^ = 66%; Figure [3B](#F3){ref-type="fig"}, bottom panel).

![Forest plot demonstrating the **(A)** mean T~peak~ -- T~end~ intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and **(B)** mean T~peak~ -- T~end~/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in AV block-induced QT prolongation.](fphys-09-01226-g0003){#F3}

Finally, QTc intervals for event-negative (Figure [4A](#F4){ref-type="fig"}, top panel) and event-positive groups (Figure [4A](#F4){ref-type="fig"}, middle panel) took values of 412 ± 104 and 594 ± 17, respectively, with a significant difference between both groups (180 ± 80 ms; *P* = 0.02; I^2^ = 99%; Figure [4A](#F4){ref-type="fig"}, bottom panel). Heart rates for event-negative (Figure [4B](#F4){ref-type="fig"}, top panel) and event-positive groups (Figure [4B](#F4){ref-type="fig"}, middle panel) took values of 56 ± 9 and 58 ± 9, respectively, with no significant mean difference between both groups (2 ± 1 ms; *P* = 0.26; I^2^ = 0%; Figure [4B](#F4){ref-type="fig"}, bottom panel).

![Forest plot demonstrating the **(A)** mean QTc intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and **(B)** mean heart rate in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation.](fphys-09-01226-g0004){#F4}

Discussion {#s4}
==========

The major findings of this systematic review and meta-analysis of 308 acquired LQTS subjects are that T~peak~ -- T~end~ intervals were longer by 76 ± 26 ms and T~peak~ -- T~end~/QT ratios were higher by 0.14 ± 0.03 in those who exhibited adverse events compared with those who did not. QTc were also longer by 180 ± 80 ms but no difference in heart rate was observed.

T~peak~ -- T~end~ represent the global dispersion of repolarization (Xia et al., [@B36]) and its prolongation has been associated with arrhythmogenesis in conditions such as Brugada syndrome, heart failure, myocardial infarction (Tse et al., [@B30],[@B32]). Recently, our group conducted a meta-analysis of the predictive values of T~peak~ -- T~end~ and T~peak~ -- T~end~ / QT ratios in congenital LQTS (Tse et al., [@B29]). This study extends these findings by providing evidence that T~peak~ -- T~end~ intervals and T~peak~ -- T~end~/QT ratios are valuable for risk stratification in acquired QT prolongation. Importantly, it shows that such have different risks of adverse outcomes, and that T~peak~ -- T~end~ intervals, T~peak~ -- T~end~/QT ratios and QTc intervals can be used to identify those who are most at risk. Besides the studies included in this meta-analysis, a large retrospective study compared the outcomes between 293 acquired LQTS subjects and 542 subjects without LQTS (Yu et al., [@B38]). They found significantly longer QTC intervals associated with higher incidences of life-threatening ventricular arrhythmias as well as one-year mortality in the acquired LQTS group. However, there was no further risk stratification within the acquired LQTS group into survivors and non-survivors using the different ECG indices reported here. Further work is needed to examine whether T~peak~ -- T~end~, T~peak~ -- T~end~/QT ratio and QTc interval are significant predictors of arrhythmic and mortality events, and to compare their relative sensitivity and specificity.

In our meta-analysis, patients with acquired LQTS due to both drugs and complete AV block were included. Clearly, the mechanisms underlying QT prolongation in these respective groups are different. Thus, drugs that inhibit the outward potassium ion channels can lead to delayed ventricular repolarization, leading to action potential prolongation and lengthening of the QT interval. Whilst drug or metabolic causes of QT lengthening are more common, the original descriptions of *torsade de pointes* associated with QT prolongation by Dessertenne involved complete AV block (Dessertenne, [@B8]). The underlying causes may be dysfunction of more than one potassium ion channel (Topilski et al., [@B27]). Our subgroup analysis found that T~peak~ -- T~end~/QT ratios, but not T~peak~ -- T~end~ intervals, were higher in event-positive subjects with drug-induced LQTS, whereas the converse was true for patients with AV block. However, this may be due to the small sample size and number of studies included.

In addition to QT, QTc, T~peak~ -- T~end~ intervals and T~peak~ -- T~end~/QT ratio, additional ECG parameters have been proposed for risk stratification (Tse and Yan, [@B35]). Static markers such as JT~Peak~ prolongation have been shown to predict adverse events in drug-induced LQTS beyond QTc (Johannesen et al., [@B14]). A new biomarker termed index of Cardiac Electrophysiological Balance (iCEB), an ECG surrogate of excitation wavelength (Tse, [@B28]), has been shown to predict ventricular arrhythmias associated with dofetilide-induced QT prolongation (Lu et al., [@B16]) and beyond (Robyns et al., [@B23]). Dynamic markers include T-wave alternans (TWA) (Zareba et al., [@B39]), microvolt TWAs (Takasugi et al., [@B25]), beat-to-beat variability in repolarization (Couderc et al., [@B6], [@B5]; Hinterseer et al., [@B13], [@B11], [@B12]; Pueyo et al., [@B22]) and restitution indices (Nicolson et al., [@B19], [@B20]), all of which have demonstrated predictability for arrhythmic outcomes. These dynamic markers may be provide additional value beyond QTc intervals, as illustrated by the findings that short-term variability in QT intervals was higher in drug-induced LQTS compared to controls, whereas QTc interval was not significantly different between these two groups (Hinterseer et al., [@B13]). It is unsurprising that variability in repolarization, rather than just the baseline repolarization properties, can further provide risk stratification because arrhythmias do not occur in every individual with prolonged QTc or T~peak~ -- T~end~ intervals. Instead, these dynamic factors can either initiate the arrhythmia or provide an additional abnormal substrate that further elevates the risk of re-entry (Thomsen et al., [@B26]; Tse et al., [@B33]).

Limitations {#s5}
===========

The following limitations should be recognized. Firstly, the heterogeneity was substantial in our meta-analysis of the mean difference for T~peak~ -- T~end~ intervals, with *I*^2^ taking a value of 98%. This compared to a low level of heterogeneity for T~peak~ -- T~end~/QT ratios with I^2^ of 29%. The reason may be due to different methods for determining T~end~, which significantly affects the values of T~peak~ -- T~end~ intervals obtained. Two studies used the tangent method by taking the intersection of a tangent to the steepest downslope of the dominant repolarization wave with the isoelectric line, whereas the remaining study used the point at which the T-wave intersected with the isoelectric line. By contrast, T~end~ cancels out in T~peak~ -- T~end~/QT ratios as it appears in both the numerator and denominator, thereby reducing the influence of T~end~ on the calculated ratio. Secondly, considerable inter-observer variability is likely present because T~peak~ -- T~end~ were measured by investigators from different research groups. Thirdly, recall bias may have been present in the retrospective studies, which could have also contributed to some of the heterogeneity observed. Fourthly, the baseline characteristics of the included studies were different, in that one study examined outcomes in the pediatric population whereas two studies were on adult populations. Fifthly, electrolyte abnormalities, most frequently hypokalemia, can also lead to delayed repolarization and consequently QT lengthening (Lee et al., [@B15]; Hanton et al., [@B10]; Tse et al., [@B31],[@B34]). Thus, potassium levels can be a confounder in further altering the QT interval. Further studies should therefore specify the plasma K+ concentrations at the time of ECG measurements where possible. Finally, although traditionally prolonged QT intervals have been categorized into congenital and acquired causes, recent epidemiological studies reveal a complex relationship between genetics and the environment. Specifically, missense variants in ion channel genes such as the SCN5A that encode for the cardiac voltage-gated sodium channel, can potentiate the effects of hypokalaemia-induced QT prolongation (Akylbekova et al., [@B1]).

Conclusions {#s6}
===========

In the context of acquired QT prolongation, T~peak~ -- T~end~ intervals were longer and T~peak~ -- T~end~ / QT ratios were higher in patients showing adverse events than in those who did not suffer from these events. These repolarization indices may therefore be useful for risk stratification in this patient population.
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